Organon (OGN) Change in Intangibles (2021 - 2025)
Organon (OGN) posted quarterly Change in Intangibles of $69.0 million for Q3 2025, up 200.0% year-over-year from $23.0 million in Q3 2024, and up 25.45% on a QoQ basis from $55.0 million in Q1 2025.
Organon (OGN) Change in Intangibles (2021 - 2025) Analysis & Trends
Organon (OGN) has reported Change in Intangibles for 5 consecutive years, with $69.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Change in Intangibles rose 200.0% year-over-year to $69.0 million; the TTM figure through Mar 2026 stood at $69.0 million (down 37.27% YoY), while the FY2025 annual figure was $124.0 million, up 18.1% from the prior year.
- Change in Intangibles came in at $69.0 million for Q3 2025 at Organon, up from $55.0 million in the prior quarter.
- The five-year high for Change in Intangibles was $192.0 million in Q2 2021, with the low at $2.0 million in Q4 2023.
- Average Change in Intangibles over 5 years is $51.0 million, with a median of $35.5 million recorded in 2022.
- Across the five-year window, Change in Intangibles plunged 79.69% in 2022 and jumped 1500.0% in 2024, its largest moves.
- Year by year, Change in Intangibles stood at $192.0 million in 2021, then plunged by 90.62% to $18.0 million in 2022, then slumped by 88.89% to $2.0 million in 2023, then surged by 1500.0% to $32.0 million in 2024, then jumped by 115.62% to $69.0 million in 2025.
- According to Business Quant data, Change in Intangibles over the past three periods registered $69.0 million, $55.0 million, and $32.0 million for Q3 2025, Q1 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -991.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -461.00 Mn |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 69.00 Mn |
| Sep 30, 2025 | 69.00 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Dec 31, 2024 | 32.00 Mn |
| Dec 31, 2024 | 32.00 Mn |
| Sep 30, 2024 | 23.00 Mn |
| Sep 30, 2024 | 23.00 Mn |
| Mar 31, 2024 | 50.00 Mn |
| Mar 31, 2024 | 50.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2022 | 18.00 Mn |
| Sep 30, 2022 | 18.00 Mn |
| Jun 30, 2022 | 39.00 Mn |
| Jun 30, 2022 | 39.00 Mn |
| Mar 31, 2022 | 30.00 Mn |
| Mar 31, 2022 | 30.00 Mn |
| Jun 30, 2021 | 192.00 Mn |
| Jun 30, 2021 | 192.00 Mn |